Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$9.50 – $14.17
9% from low
Exchange
OTC Link
ADRC
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.43B | $1.52B | $1.43B | $1.68B | $1.76B | $1.97B | $2.26B | $2.34B |
| Cost of revenue | $288.1M | $305.7M | $282.2M | $340.6M | $379.6M | $395.7M | $452.4M | $1.71B |
| Gross profit | $1.14B | $1.22B | $1.15B | $1.34B | $1.38B | $1.57B | $1.81B | $630.2M |
| Gross margin | 79.8% | 79.9% | 80.3% | 79.7% | 78.4% | 79.9% | 80.0% | 26.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $249.9M | $257.3M | $339.0M | $219.2M | $235.4M | $286.5M | $341.7M | $310.8M |
| EBITDA | $296.9M | $385.2M | $328.7M | $397.2M | $347.0M | $413.7M | $475.7M | $531.5M |
| Net income | $168.9M | $172.2M | $116.4M | $136.9M | $103.7M | $127.6M | $152.1M | $195.7M |
| Net margin | 11.8% | 11.3% | 8.1% | 8.2% | 5.9% | 6.5% | 6.7% | 8.4% |
| EPS (diluted) | 0.40 | 0.41 | 0.28 | 0.33 | 0.25 | 0.30 | 0.36 | 0.47 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.6B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $2.7B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
FIELMANN GROUP AG U/ADR
No one on the platform currently holds FLMNY.
No tracked institution reports a position in FLMNY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-13 | $0.3249 | 2026-08-03 |
| 2025-07-14 | $0.2682 | 2025-07-30 |
| 2024-07-15 | $0.2176 | 2024-07-31 |
| 2023-07-14 | $0.1682 | 2023-08-02 |
No one on the platform has traded FLMNY yet.
| $3.3B |
| — |
| CSMYFCOSMOS Pharmaceutical Corporation | $37.06 | +0.00% | $2.9B | — |
| CZMWFCarl Zeiss Meditec AG | $30.00 | +0.00% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 26.3× earnings vs its 28.7× historical median P/E.
Fair value ≈ $10.85 · price $9.94 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.